Profile data is unavailable for this security.
About the company
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
- Revenue in EUR (TTM)303.66m
- Net income in EUR-60.61m
- Incorporated1999
- Employees683.00
- LocationGalapagos NVGeneraal De Wittelaan L11 A3MALINES (MECHELEN) 2800BelgiumBEL
- Phone+32 15342900
- Fax+32 15342901
- Websitehttps://www.glpg.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Puretech Health PLC | 449.27k | -79.17m | 495.25m | 90.00 | -- | 1.63 | -- | 1,102.33 | -0.2401 | -0.2401 | 0.0014 | 1.05 | 0.0007 | -- | 0.2252 | 4,149.70 | -14.13 | 4.92 | -16.35 | 5.94 | -- | -- | -19,222.22 | 352.67 | -- | -- | 0.0728 | 0.00 | -78.68 | -30.64 | -30.47 | -- | -44.10 | -- |
| Abivax SA | 0.00 | -177.43m | 534.21m | 62.00 | -- | 4.20 | -- | -- | -3.20 | -3.20 | 0.00 | 2.01 | 0.00 | -- | -- | 0.00 | -77.89 | -65.49 | -107.73 | -97.67 | -- | -- | -- | -- | -- | -110.67 | 0.4334 | -- | -- | -- | -111.52 | -- | -19.06 | -- |
| Oxford BioMedica plc | 117.03m | -170.84m | 535.17m | 834.00 | -- | 6.67 | -- | 4.57 | -1.44 | -1.44 | 0.9642 | 0.6292 | 0.3012 | 4.09 | 4.21 | 136,252.10 | -51.98 | -19.60 | -66.85 | -24.68 | 36.74 | 50.74 | -172.59 | -44.38 | 2.07 | -12.47 | 0.6077 | -- | -36.04 | 6.04 | -302.20 | -- | -0.6307 | -- |
| Philogen SpA | 2.28m | -29.35m | 580.47m | 174.00 | -- | 10.55 | -- | 254.15 | -0.7301 | -0.7301 | 0.0568 | 1.88 | 0.0191 | 5.55 | 1.57 | 14,275.00 | -24.49 | -7.32 | -27.75 | -8.36 | -564.19 | 32.04 | -1,285.03 | -58.66 | 5.02 | -- | 0.155 | -- | -2.46 | 10.80 | -14.60 | -- | 51.78 | -- |
| Basilea Pharmaceutica AG Allschwil | 160.03m | -700.16k | 584.09m | 156.00 | -- | 29.82 | 473.79 | 3.65 | -0.2814 | -0.2814 | 11.54 | 1.38 | 0.7118 | 1.22 | 4.40 | 1,013,755.00 | -0.3114 | -1.86 | -0.4156 | -2.99 | 76.57 | 83.45 | -0.4375 | -2.99 | 3.27 | -1.38 | 0.8508 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
| Formycon AG | 60.80m | 63.90m | 827.23m | 239.00 | 11.71 | 1.44 | 12.54 | 13.61 | 4.00 | 4.00 | 3.64 | 32.64 | 0.0654 | 34.46 | 1.55 | 255,462.20 | 6.87 | 5.87 | 7.37 | 6.33 | 12.46 | 28.54 | 105.09 | 39.76 | 2.06 | -- | 0.0185 | 0.00 | 82.83 | 12.47 | 110.59 | 60.58 | 81.87 | -- |
| Kuros Biosciences AG | 56.42m | -9.54m | 980.92m | 80.00 | -- | 14.85 | -- | 17.38 | -0.2295 | -0.2295 | 1.73 | 1.64 | 0.6755 | 1.95 | 7.89 | 656,775.00 | -11.42 | -13.47 | -13.53 | -14.84 | 79.13 | 78.73 | -16.91 | -81.48 | 2.17 | -- | 0.0847 | -- | 86.61 | 115.93 | 5.95 | -- | -13.21 | -- |
| BioArctic AB | 14.54m | -20.25m | 1.21bn | 104.00 | -- | 18.24 | -- | 83.56 | -2.64 | -2.64 | 1.89 | 10.39 | 0.1431 | -- | -- | 1,899,330.00 | -19.94 | 2.24 | -22.13 | 2.56 | 80.72 | 86.52 | -139.32 | 9.76 | -- | -- | 0.0578 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | 11.83 | -- |
| Genus plc | 804.54m | 9.50m | 1.36bn | 3.44k | 144.83 | 2.07 | 22.97 | 1.70 | 0.1186 | 0.1186 | 10.14 | 8.30 | 0.6569 | -- | 5.84 | 194,475.10 | 0.2357 | 3.30 | 0.2742 | 3.87 | -- | -- | 0.3589 | 4.98 | 1.21 | 93.17 | 0.3487 | 62.72 | -3.03 | 6.48 | -76.28 | 0.2551 | -2.68 | 2.93 |
| Gubra A/S | 30.01m | -6.24m | 1.41bn | 235.00 | -- | 22.64 | -- | 47.04 | -2.82 | -2.82 | 13.54 | 28.44 | 0.3627 | -- | 8.07 | 1,021,986.00 | -7.54 | -- | -8.33 | -- | 58.74 | -- | -20.79 | -- | -- | -- | 0.1647 | -- | 2.82 | -- | -1,133.04 | -- | -- | -- |
| Evotec SE | 777.05m | -171.37m | 1.51bn | 5.01k | -- | 1.56 | -- | 1.94 | -0.9668 | -0.9668 | 4.39 | 5.46 | 0.3661 | 19.82 | 5.22 | 153,537.30 | -8.07 | -0.0064 | -9.86 | -0.0076 | 13.70 | 24.51 | -22.05 | -0.0178 | 1.99 | -3.11 | 0.3268 | 0.00 | 3.99 | 15.79 | 52.23 | -- | 50.62 | -- |
| Galapagos NV | 303.66m | -60.61m | 1.67bn | 683.00 | -- | 0.5843 | -- | 5.51 | -0.9096 | 3.14 | 4.61 | 43.44 | 0.0704 | 0.3157 | 6.58 | 470,055.70 | -1.41 | -1.48 | -1.55 | -1.65 | 65.10 | -- | -19.96 | -14.42 | 9.95 | -- | 0.004 | -- | 3.47 | -2.02 | 94.42 | -- | 7.04 | -- |
| BB BIOTECH AG | 290.66m | 134.62m | 2.16bn | -- | 15.98 | 0.8917 | -- | 7.42 | 2.27 | 2.27 | 4.95 | 40.66 | 0.1077 | -- | -- | -- | 4.99 | 2.34 | 5.64 | 2.52 | 97.86 | 99.06 | 46.32 | 35.40 | -- | 2.17 | 0.1096 | 217.78 | -57.97 | -37.98 | 42.26 | -- | -- | -8.09 |
Data as of Nov 25 2024. Currency figures normalised to Galapagos NV's reporting currency: Euro EUR
9.66%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 06 Nov 2024 | 1.75m | 2.66% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 958.10k | 1.45% |
| Wellington Management Co. LLPas of 31 Jul 2024 | 858.63k | 1.30% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 715.78k | 1.09% |
| Dimensional Fund Advisors LPas of 31 Oct 2024 | 709.87k | 1.08% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 560.02k | 0.85% |
| Schroder Investment Management Ltd.as of 31 Jul 2024 | 325.77k | 0.49% |
| BlackRock Advisors (UK) Ltd.as of 08 Nov 2024 | 186.91k | 0.28% |
| De Grote Voskuil Capital BVas of 31 Dec 2023 | 180.00k | 0.27% |
| PRIMECAP Management Co.as of 29 Jun 2024 | 115.54k | 0.18% |
More ▼
Data from 31 Dec 2023 - 30 Sep 2024Source: FactSet Research Systems Inc.
